Nina Skorytchenko
Nina Skorytchenko is a speaker on prognostic and predictive technologies for chronic inflammatory diseases.
As CEO of Avenna, she brings deep expertise in precision medicine, combining clinical insight with multi-omics innovation to drive personalised healthcare solutions.
Her talks explore the future of biomarker-driven diagnostics, the integration of predictive tools in clinical development, and the impact of systems biology on therapeutic decision-making.
Past Speaking Engagements
4th ACE Clinical Trial Summit
2nd-3rd April 2025 London, UK.
The Headline of her session is “How Precision Medicine Technologies Can be Used as a Complementary Diagnostics to Optimise Clinical Trial Efficiency “
Join us if you want to learn about multi-omics and combination biomarker approach and how they can be integrated into your clinical trial.
15th Annual Outsourcing in Clinical Trials Europe 2025
29th April 20205 Barcelona, Spain
Moderated the panel “Embracing Innovative Technologies in Clinical Trials: Opportunities and Challenges” alongside Dr. Fabian Kreimendahl (Johnson & Johnson Innovative Medicine), Sonja Weiser PhD (Insmed Incorporated), and Daniel Martinez Alcazar (Exeltis).
The session examined why pharma often takes up to seven years to adopt new technologies, as noted in a 2022 Tufts study. The discussion focused on the potential of AI-driven models, ePROs, and EHR-to-EDC data transfers to streamline clinical trials—while also addressing critical challenges such as explainable AI, data privacy, and regulatory engagement. The panel emphasised the need for cross-sector collaboration to accelerate innovation across the industry.
4th Pharmacovigilance and Drug Safety Conference
30th April 2025 Barcelona, Spain
Delivered a presentation titled “How Precision Medicine Technologies Can Be Used as a Complementary Diagnostic to Optimise Clinical Trial Efficiency.”
The session explored how pharmacovigilance is evolving to incorporate precision medicine approaches. Nina highlighted the potential of glycomic biomarkers to provide valuable insights into immune function, inflammation, and metabolic health — all closely linked to adverse drug reactions. The talk emphasised how these technologies can strengthen safety monitoring and enhance clinical trial efficiency through more targeted patient stratification.
Clinical Outsourcing Group COG-UK
February 2024 London, UK
Participated as a panellist in an insightful discussion alongside other accomplished women in the field at the 2nd Annual Clinical Outsourcing Group UK.
The panel delved into the theme of “What innovative solutions are CROs/Vendors proposing to deliver greater value and capabilities on potentially shrinking budgets?
Nina also had the privilege of presenting how precision medicine technologies can make clinical trials more efficient. In her presentation titled “Harnessing Precision Medicine for Smarter Clinical Trials: Complementary Diagnostics to Drive Cost Efficiency and Success.” she elaborated on how Avenna’s advanced glycomic technology is pivotal in enhancing clinical trial success through complementary diagnostics, including patient stratification and treatment personalisation. Furthermore, it could serve as companion diagnostics by providing tailor-made biomarkers for developing specific drugs.
ACE Clinical Trial Summit
March, 2024 London, UK
Nina joined as an Expert Speaker at the 2nd Ace Clinical Trials Summit (ACTS).
The Headline of her session is “How Precision Medicine Technologies Can be Used as a Complementary Diagnostics to Optimise Clinical Trial Efficiency “
Clinical Data Management Innovation Europe
19 – 20th November 2024 Brussels, Belgium.
The Headline of her session is “How Precision Medicine Technologies Can be Used as a Complementary Diagnostics to Optimise Clinical Trial Efficiency “
She presented on the role of precision medicine in enhancing clinical trial efficiency through multi-omics and combination biomarker strategies.
Drawing on insights from the Innovate UK ProVision-RA project with the University of Ulster Personalised Medicine Centre, she highlighted how complementary diagnostics can improve patient stratification and reduce trial failure rates.
She also participated in a panel discussion on Driving Scalable Innovation That Will Shape the Future of Clinical Research, where she shared views on emerging technologies, the value of data-driven approaches, and the need for cross-sector collaboration in clinical innovation.
9th Annual Clinical Trial Summit Europe
28th – 29th November 2024 Barcelona, Spain.
The Headline of her session is “How Precision Medicine Technologies Can be Used as a Complementary Diagnostics to Optimise Clinical Trial Efficiency “
Here, she explained the growing significance of a multi-omics and combination biomarker approach and how it can be integrated into clinical trials, including insights from an Innovate UK ProVision-RA project with the University of Ulster Personalised Medicine Centre.
European clinical trials innovation programme
April , 2023 Dusseldorf, Germany
Presented on the topic: How to improve the success rates of clinical trials for anti-inflammatory drugs using reliable, precision medicine, biomarkers for Chronic Inflammatory Diseases (cIDs).
8th Clinical Trials Summit
June 2023 Munich, Germany
Presented at Clinical Trials Summits (CTS). CTS is an ideal program for novice clinical researchers, including investigators, coordinators, and trial monitors, to develop the foundational knowledge upon which they can develop their competence as clinical research professionals. The program is perfect for those interested in the profession or indirectly involved in clinical trials.
10th Annual Outsourcing In Clinical Trials UK & Ireland
September 2023 London, UK
Presented on the topic : Improving the success rates of clinical trials for anti-inflammatory drugs using reliable, precision medicine, biomarkers for Chronic Inflammatory Diseases (cIDs).
Pharma Integrates
November 2023 London, UK
Roundtable discussion: Titled “Trialling a New Approach to Clinical Trials.” This engaging panel, facilitated by Lord James O’Shaughnessy, Senior Partner of Newmarket Strategy, will explore the rapidly changing landscape of the pharmaceutical space, with a special focus on the innovative strides being made right here in the UK. Other panelists, including James Chennells from Bayer, Paul Wicks, an Independent Consultant and Wicks Digital Health, and Miranda Mapleton, CEO of White Swan (Charity), will share their insights and experiences. Together, they discuss how the UK can deliver more innovative trials and leverage the assets within the NHS.
Key Topics of Discussion:
- Adaptive Trials,
- Decentralised trials,
- Virtual Trials
- Transforming the UK into a Hub for Clinical Trials